Compare EXPI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | IMCR |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | EXPI | IMCR |
|---|---|---|
| Price | $8.66 | $31.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $12.00 | ★ $64.30 |
| AVG Volume (30 Days) | ★ 868.1K | 550.4K |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,678,653,000.00 | $379,590,000.00 |
| Revenue This Year | $6.03 | $32.49 |
| Revenue Next Year | $5.37 | $11.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.12 | ★ 28.11 |
| 52 Week Low | $6.90 | $23.15 |
| 52 Week High | $12.23 | $40.72 |
| Indicator | EXPI | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 28.28 | 35.90 |
| Support Level | $8.28 | $30.60 |
| Resistance Level | $9.14 | $33.49 |
| Average True Range (ATR) | 0.29 | 1.51 |
| MACD | -0.05 | -0.23 |
| Stochastic Oscillator | 8.87 | 14.02 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.